SSY GROUP (02005.HK): Baloxavir Marboxil API Approved for Registration, Becoming the Third Domestic Enterprise with Such Approval
NewTimeSpace News: On 13 July 2026, SSY GROUP (02005.HK) released a voluntary announcement. Baloxavir Marboxil of the Group has obtained registration approval from the National Medical Products Administration (NMPA) of China as an active pharmaceutical ingredient to be applied in marketed pharmaceutical formulations. The Group becomes the third domestic enterprise receiving such approval. Baloxavir Marboxil is mainly used for the treatment of Influenza A and Influenza B virus infections.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- SSY GROUP (02005.HK): Nimodipine oral solution wins production nod
- SSY GROUP (02005.HK): Ziprasidone Mesylate Approved for Registration as API for Use in Marketed Formulations
- SSY GROUP (02005.HK): Wins NMPA approval for Letermovir Injection, deemed to have passed consistency evaluation
- SSY GROUP (02005.HK): Trustee Purchases 1.2 Million Shares on Open Market
- SSY GROUP (02005.HK): Trustee purchases 1,000,000 shares under restricted share award scheme for approximately HKD 2.73 million
